Ars Pharmaceuticals, Inc. (SPRY) — 10-Q Filings

10-Q Filings (6)

• SPRY's Revenue Soars, But Mounting Losses Raise Concerns — Nov 10, 2025 Risk: high
  ARS Pharmaceuticals, Inc. (SPRY) reported a significant increase in product revenue for the nine months ended September 30, 2025, reaching $51.863 million, up f
• SPRY's Losses Widen Amid Neffy Commercialization Push — Aug 13, 2025 Risk: high
  ARS Pharmaceuticals, Inc. (SPRY) reported a significant increase in net loss to $44.88 million for the three months ended June 30, 2025, compared to $12.52 mill
• ARS Pharma Files 10-Q, Details Key Agreements — May 14, 2025 Risk: medium
  ARS Pharmaceuticals, Inc. filed a 10-Q for the period ending March 31, 2025. The company reported on its financial performance and business activities. Key agre
• ARS Pharma Files Q3 2024 10-Q — Nov 13, 2024 Risk: medium
  ARS Pharmaceuticals, Inc. filed its 10-Q for the period ending September 30, 2024. The company reported research and development expenses for the nine months en
• ARS Pharmaceuticals Files Q2 2024 10-Q — Aug 6, 2024 Risk: medium
  ARS Pharmaceuticals, Inc. filed its 10-Q for the period ending June 30, 2024. The company reported financial results and operational updates. Key financial figu
• ARS Pharmaceuticals Files 10-Q for Period Ending March 31, 2024 — May 9, 2024 Risk: low
  ARS Pharmaceuticals, Inc. (SPRY) filed a Quarterly Report (10-Q) with the SEC on May 9, 2024. ARS Pharmaceuticals, Inc. filed a 10-Q report for the period endin

Popular Companies

AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX